海王生物(000078) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was CNY 10,545,449,942.88, representing a 14.58% increase compared to CNY 9,203,779,298.47 in the same period last year[8]. - Net profit attributable to shareholders decreased by 13.49% to CNY 132,077,118.26 from CNY 152,670,666.88 year-on-year[8]. - The net profit after deducting non-recurring gains and losses fell by 18.88% to CNY 124,447,740.38 compared to CNY 153,417,268.73 in the previous year[8]. - Basic earnings per share decreased by 14.73% to CNY 0.0492 from CNY 0.0577 in the same period last year[8]. - The weighted average return on equity was 2.20%, a decrease of 0.53 percentage points compared to 2.73% in the previous year[8]. - Net profit for the current period was ¥202,135,057.50, a decrease of 6.7% from ¥216,619,993.26 in the previous period[64]. - The company reported a basic earnings per share of ¥0.0492, down from ¥0.0577 in the previous period[66]. - The company reported a significant increase in cash received from sales of goods and services, totaling approximately ¥9.59 billion, compared to ¥7.21 billion in the previous period, reflecting a growth of about 33%[76]. - The company’s net profit for the period was a loss of ¥544,490.77, compared to a loss of ¥2,563,649.75 in the previous period, showing a reduction in losses[75]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching CNY 69,452,343.45, a 106.56% increase from a negative CNY 1,058,151,313.49 in the same period last year[8]. - The net cash flow from operating activities increased by 106.56% compared to the same period last year, mainly due to the company's increased efforts in sales collections[22]. - The net cash flow generated from operating activities was ¥69.45 million, a significant recovery from a net outflow of ¥1.06 billion in the previous period[79]. - The net cash flow from financing activities decreased by 61.23% compared to the same period last year, mainly due to debt repayment during the period[22]. - The company reported cash outflows from operating activities totaling 7,534,285,120.60 CNY, significantly higher than 3,821,804,108.46 CNY in the previous period[85]. - The total cash inflow from financing activities was 2,531,139,158.17 CNY, compared to 2,647,180,000.00 CNY in the prior period, showing a slight decrease[88]. - Cash and cash equivalents at the end of the period totaled 146,349,663.67 CNY, a decrease from 414,426,931.48 CNY in the previous period[88]. - The company received cash from investment activities totaling ¥77.50 million, with cash outflows from investment activities amounting to approximately ¥197.85 million, resulting in a net cash outflow of ¥120.35 million[81]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 39,273,306,438.36, down 4.51% from CNY 41,126,743,376.46 at the end of the previous year[8]. - Total current assets decreased from ¥33.60 billion to ¥31.52 billion, a decline of approximately 6.2%[44]. - Total non-current assets increased from ¥7.52 billion to ¥7.76 billion, an increase of about 3.2%[44]. - Total liabilities decreased from ¥34.01 billion to ¥31.42 billion, a decrease of approximately 7.6%[47]. - The total liabilities amounted to ¥8,724,147,159.92, slightly down from ¥8,851,889,947.41[60]. - The total equity increased to ¥5,762,809,310.89 from ¥5,510,511,837.11, representing a growth of 4.6%[60]. - The total assets reached ¥14,486,956,470.81, compared to ¥14,362,401,784.52 previously, showing a slight increase[60]. - The total assets amounted to 41,126,743,376.46 CNY, remaining stable compared to the previous reporting period[92]. Government Support and Other Income - The company received government subsidies amounting to CNY 10,061,881.28 during the reporting period, primarily from support funds[8]. - Other income increased by 289.4% compared to the same period last year, primarily due to government subsidies received by subsidiaries[22]. Expenses and Costs - Total operating costs amounted to ¥10,257,005,335.54, up from ¥8,903,306,604.03, reflecting a growth of 15.2%[61]. - Financial expenses increased by 54.2% compared to the same period last year, mainly due to an increase in the borrowing base and rising market interest rates[22]. - The company incurred operating expenses of approximately ¥13.33 billion, slightly higher than ¥13.18 billion in the previous period, indicating a marginal increase[79]. - Research and development expenses for the current period were ¥10,334,180.91, indicating ongoing investment in innovation[61].